Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lutetium 177Lu Vipivotide Tetraxetan→

Lutetium 177Lu Vipivotide Tetraxetan PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1703749-62-5
Molecular formula
C49H68[177Lu]N9O16
Molecular weight
1216.1 g/mol
Drug class
Therapeutic radiopharmaceuticalprostate-specific membrane antigen (PSMA)-targeted radioligand therapy
Mechanism of action
A small-molecule ligand binds with high affinity to PSMA on prostate cancer cells and delivers beta-minus radiation from lutetium-177. The emitted radiation induces DNA damage in targeted and nearby cells, potentially leading to cell death.
Indications / reported uses
  • Treatment of adults with PSMA-positive metastatic prostate cancer under the applicable product label; patient selection and approved treatment setting depend on prior androgen-receptor pathway therapy and taxane exposure.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a · https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto · https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Therapeutic radiopharmaceutical; prostate-specific membrane antigen (PSMA)-targeted radioligand therapy

Mechanism of action

A small-molecule ligand binds with high affinity to PSMA on prostate cancer cells and delivers beta-minus radiation from lutetium-177. The emitted radiation induces DNA damage in targeted and nearby cells, potentially leading to cell death.

General use cases

  • Treatment of adults with PSMA-positive metastatic prostate cancer under the applicable product label; patient selection and approved treatment setting depend on prior androgen-receptor pathway therapy and taxane exposure.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Lutetium 177Lu Vipivotide Tetraxetan PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lutetium 177Lu Vipivotide Tetraxetan Permitted Daily Exposure (PDE) report (the Lutetium 177Lu Vipivotide Tetraxetan PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lutetium 177Lu Vipivotide Tetraxetan Occupational Exposure Limit (OEL) report (the Lutetium 177Lu Vipivotide Tetraxetan OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.